Search Page
Save citations to file
Email citations
Email address has not been verified. Go to
My NCBI account settings
to confirm your email and then refresh this page.
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2020 | 1 |
| 2025 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial.
Clin Cancer Res. 2020 Apr 1;26(7):1586-1594. doi: 10.1158/1078-0432.CCR-18-1140. Epub 2020 Feb 7.
Clin Cancer Res. 2020.
PMID: 32034072
Free article.
ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma.
Gatson NT, Weathers SP, de Groot JF.
Gatson NT, et al.
CNS Oncol. 2016;5(1):11-26. doi: 10.2217/cns.15.38. Epub 2015 Dec 15.
CNS Oncol. 2016.
Retraction in:
CNS Oncol. 2016;5(2):110. doi: 10.2217/cns.16.1.
PMID: 26670466
Free PMC article.
Retracted.
Item in Clipboard
Cite
Cite
ARTICLE TYPE
ARTICLE LANGUAGE
AGE
Filters on the sidebar will be reset to the default list and any currently applied filters will be cleared.